Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

#### 144: Filer Information

Filer CIK 0001967168
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

#### 144: Issuer Information

Name of Issuer Enliven Therapeutics, Inc.

SEC File Number 001-39247

6200 LOOKOUT ROAD

Address of Issuer

BOULDER
COLORADO

80301

Phone 720-647-8519

Name of Person for Whose Account the Securities are To Be Sold

Kintz Samuel

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Securities
Common	Jefferies LLC 520 Madison Ave New York NY 10022	12000	288120.00	47000000	07/25/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
-----------------------	----------------------	-----------------------------------	--	--------------------------	---------------------------	-------------------------------------	--------------------	------------------------

06/12/2019 Founder Shares Enliven 12000 06/12/2019 N/A Common **Therapeutics** 

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	<b>Gross Proceeds</b>
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therpeutics	05/28/2024	12000	278210.40
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	04/25/2024	12000	202700.76
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	04/11/2024	47709	1194702.06
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	06/25/2024	12000	259901.16

# 144: Remarks and Signature

Remarks

All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 06/26/2023, and all representations regarding material non-public information were made as of the adoption of the plan. The shares in this filing will be sold from THE KINTZ & EGAN TRUST UAD

03/30/19.

Date of Notice 07/25/2024

Date of Plan Adoption

or Giving of Instruction, 1f Relying on Rule 10b5-

#### **ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Samuel Kintz

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.